Focusing on Clinical R&D Opportunities | Leadingpharm Shines at the 2026 DIA Drug Information Conference

May 13–16, 2026 – The 2026 DIA Drug Information Conference and Exhibition was grandly held at the Shanghai Zhangjiang Science Hall. As a highly anticipated annual event in drug development, regulatory science, and industry collaboration, this year’s conference conducted in‑depth exchanges on new drug development, international regulatory cooperation, clinical value translation, healthcare payment, and innovation ecosystems, continuously promoting deep integration of China’s and global pharmaceutical innovation. Leadingpharm, with its deep expertise in the clinical CRO field and its service philosophy of “End‑to‑End, Top‑Level Design, Being the Full‑Process Partner for Innovative Drug Clinical Services,” brought its clinical expert team and rich project experience to the 2026 DIA conference.
 

The exhibition hall was crowded and vibrant. Leadingpharm’s booth stood out as a focal point, attracting numerous clinical researchers, pharma R&D leaders, industry experts, and partners for exchange. The expert team was on site throughout, engaging in deep discussions with visitors on core topics such as innovative drug clinical study design, bioequivalence studies, IND application strategies, clinical trial quality control, and international multi‑center clinical collaboration.
 

Combining the latest domestic and international regulatory requirements and real‑world cases, the expert team shared solutions for clinical R&D challenges, risk management experiences, and industry frontier trends, precisely addressing queries from visitors on project progress. From early‑stage clinical protocol optimization to later‑stage registration submission, and from domestic compliance to international market deployment, the open and sincere exchanges deepened mutual understanding of industry developments and resulted in multiple cooperation intentions.
 

This appearance at the 2026 DIA conference was an important step for Leadingpharm to align with international standards, deepen collaboration, and empower innovation. Going forward, Leadingpharm will continue to uphold its original aspiration, refine its expertise, continuously optimize its service system, upgrade its technical capabilities, and provide more professional and efficient services to become the most trusted full‑process partner for new drug development for domestic and international clients. With outstanding clinical research capabilities, it will help bring more high‑quality new drugs to market faster and contribute to the high‑quality development of the global pharmaceutical and healthcare industry.
 

About Us

Deep Blue Ocean Biopharmaceutical is the clinical CRO sub‑brand of Leadingpharm (stock code 600222), established in 2007. Adhering to the philosophy “End‑to‑End, Top‑Level Design, Being the Full‑Process Partner for New Drug Development,” it provides global pharmaceutical companies with services covering Phase I‑III clinical studies, bioequivalence studies, third‑party auditing, IND application strategy guidance, and medical affairs for biologics, chemical drugs, TCM, medical devices, and cell & gene therapies. It meets the customized clinical research needs of various R&D‑oriented companies and helps clients overcome key bottlenecks before new drug launch.

To date, the company has conducted over 2,000 clinical research projects. In cell & gene therapy and aesthetic medicine, multiple projects have achieved domestic/international first‑in‑human or first‑approved status, filling gaps in China and globally. It also possesses extensive experience and resource accumulation in endocrinology, cardiovascular, oncology, rheumatology & immunology, pediatrics, rare diseases, and neuropsychiatry.

-END-